Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quetiapine extended release Clear all
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency

NCT00498628
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Quetiapine fumarate, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 22, 2026, 6:18 AM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

NCT00880919
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
quetiapine extended-release, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Belmont, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

NCT01165541
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Bedford, New Hampshire • Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 8, 2018 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

NCT00579280
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
quetiapine SR, divalproex sodium ER, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

NCT00671853
View directory record Official record
Conditions
Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
Interventions
Quetiapine XR, Placebo for quetiapine XR
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

NCT01971203
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
seroquel xr, CBT
Drug · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 22, 2026, 6:18 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

NCT00702676
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Sep 22, 2026, 6:18 AM EDT
Terminated Phase 3 Interventional

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

NCT00315900
View directory record Official record
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Brexpiprazole, Quetiapine extended release
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Not applicable Interventional Results available

Quetiapine for the Reduction of Cocaine Use

NCT00631748
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
Interventions
quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
Drug · Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 22, 2026, 6:18 AM EDT
Terminated Phase 3 Interventional Results available

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

NCT00868374
View directory record Official record
Conditions
Major Depressive Disorder, Generalized Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Keming Gao
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

NCT00397020
View directory record Official record
Conditions
Bipolar Disorder
Interventions
divalproex ER, quetiapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 22, 2026, 6:18 AM EDT
Terminated Early Phase 1 Interventional

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

NCT00606541
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Bipolar Depression

NCT00811473
View directory record Official record
Conditions
Bipolar Depression
Interventions
Quetiapine XR, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 22, 2026, 6:18 AM EDT
Completed Phase 3 Interventional

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 22, 2026, 6:18 AM EDT